Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain.

Prior treatment

• Other concomitant neoplasia (progressive or not).
• Previous treatment with capsaicin or amitriptyline.
• Topical treatment of the painful area used for more than 21 days before inclusion.

Other illness

• ORL cancer in progression.
• Allergy to any of the components of the capsaicin patch.
• Uncontrolled high blood pressure or cardiovascular history (infarction, stroke, pulmonary embolism) less than 3 months ago.
• Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.

Other

• Central etiology of pain.
• Pain whose average intensity over the last 24 hours is assessed on the numerical scale as \< 2/10.
• Capsaicin patch not applicable to the area to be treated despite the precautions described in the protocol because of its proximity to mucous membranes or eyelids.
• Contraindication to amitriptyline treatment.
• Patient with an unhealed skin lesion on the area to be treated.
• Ongoing opioid treatment \> 80mg/day oral morphine equivalent.
• Patient included in another interventional therapeutic trial.
• Pregnant or breastfeeding patient.
• Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

• Age ≥ 18 years.
• ORL cancer in remission: absence of clinical or radiological signs of progression at least 3 months after specific treatments.
• Pain of the cervico-facial sphere persisting for more than 3 months after surgical and/or radiotherapy treatment.
• Peripheral neuropathic character of pain objectified to a score ≥ 4/10 on the DN4 questionnaire.
• Pain whose average intensity over the last 24 hours is assessed on the numerical scale as ≥ 2/10.
• Postmenopausal patient or patient who agrees to use effective contraception for the duration of treatment and for a minimum of 15 days after the end of the treatment period. Non-menopausal patients must have a negative pregnancy test prior to inclusion in the study.
• Patient affiliated to a Social Health Insurance in France.
• Patient who signed informed consent prior to inclusion in the study and prior to any specific study procedures.